Dec. 1 at 1:03 PM
Cantor reitd
$LXEO OW/
$19 after survey
$LRMR $BIIB
Cantor
Overall sentiment was very positive on LXEO, with investors expressing that the value of FA cardiomyopathy (AAVrh10- based gene therapy, LX2006) alone is undervalued (although consensus is that LXEO has a good case to support a broad FA label). Beyond this, there is some excitement around PKP2-ACM, especially as LXEO could differentiate on safety, and it represents a significant market opportunity.
That said, to an extent, we still think it is under the radar and not all investors we we have spoken with appreciate the level of data LXEO has generated to date and what will be coming in January. Thus, upcoming PKP2-ACM data could put LXEO on more investor radars. Some investors are still questioning the regulatory path for gene therapy overall, and we'd highlight it's critical to understand key differences between companies and approaches. In particular, we emphasize LXEO has established its pivotal plans prior to starting this study.
